A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)

Summary

This is a 1-year study to assess the safety, tolerability, and efficacy of an investigational drug in obese patients after a very low calorie diet.

Timeline

Start

2003-11

Primary completion

2005-02

Completion

2005-02

Outcome

Met primary endpoint

paper Although statistically significant at 52 weeks, the magnitude of induced weight loss was not clinically meaningful. PMID 17011500 ↗

Publications

• Results Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, Cote J, Bray G, Fujioka K, Bays H, Hollander P, Sanabria-Bohorquez SM, Eng W, Langstrom B, Hargreaves RJ, Burns HD, Kanatani A, Fukami T, MacNeil DJ, Gottesdiener KM, Amatruda JM, Kaufman KD, Heymsfield SB. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006 Oct;4(4):275-82. doi: 10.1016/j.cmet.2006.08.002.

Drugs

Indications